"I don't think a US listing is a magic bullet but it can unlock huge value if done properly. To me before a US listing there needs to be a clear path forward both clinically and financially so that investors have strong, real reasons to embrace the new listing. "

Here is a simple path forward:

1.  Immediate 10 for 1 roll-back/share consolidation  (approx. 30 million shares post consolidation)

2.  Apply for NASDAQ listing.

3.  Find a reputable/experienced US broker dealer.

4.  Arrange for immediate $175M (USD) share issue through said broker dealer (so $approx $350 - 375M USD market cap post financing)

5.  Explain to the market this is to fund a 4500 patient Phase 3b CVOT with interim efficacy analysis (as part of the BTD).

6.  The value proposition/payoff upon successful interim analysis would be worth several $B USD. (pick a number)

7.  Announce the trial starts July 2021.

8.  Damn the torpedos, full steam ahead.  Screw this tepid s**t.  We need a bold move.